Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Sonja Zweegman"'
Autor:
Michele Cavo, Ioannis Ntanasis-Stathopoulos, Charalampia Kyriakou, Brian G.M. Durie, Jesús F. San-Miguel, Fredrik Schjesvold, Philippe Moreau, Sonja Zweegman, Noopur Raje, Evangelos Terpos, Nikhil C. Munshi, Matthew T. Drake, Meletios A. Dimopoulos, Elena Zamagni, Suzanne Lentzsch, Niels Abildgaard, Jens Hillengass, Javier de la Rubia, Ramón García-Sanz
Publikováno v:
Terpos, E, Zamagni, E, Lentzsch, S, Drake, M T, García-Sanz, R, Abildgaard, N, Ntanasis-Stathopoulos, I, Schjesvold, F, de la Rubia, J, Kyriakou, C, Hillengass, J, Zweegman, S, Cavo, M, Moreau, P, San-Miguel, J, Dimopoulos, M A, Munshi, N, Durie, B G M, Raje, N & Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045(20)30559-3
Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045(20)30559-3
Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045(20)30559-3
In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading r
Autor:
Marian Stevens-Kroef, M. van Marwijk Kooy, Henk M. Lokhorst, Hans-Walter Lindemann, Anna Potamianou, Gerard M. J. Bos, B. van der Holt, Igor Wolfgang Blau, Annemiek Broijl, Christoph Scheid, Peter Brossart, Pieter Sonneveld, Sonja Zweegman, R. Schaafsma, Sandra Croockewit, Reinier Raymakers, Le Jarari, Ulrich Duehrsen, H Salwender, Jens Hillengass, Dirk Hose, Elias K. Mai, Anna Jauch, Marc-Steffen Raab, Michael Pfreundschuh, Thomas Hielscher, Paula F. Ypma, Marie-Jose Kersten, Katja Weisel, Edo Vellenga, H. Goldschmidt, Uta Bertsch
Publikováno v:
Leukemia, 32(2), 383-390. Nature Publishing Group
Leukemia, 32, 2, pp. 383-390
Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, L, Salwender, H J & Sonneveld, P 2018, ' Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial ', Leukemia, vol. 32, no. 2, pp. 383-390 . https://doi.org/10.1038/leu.2017.211
Leukemia, 32(2), 383. Nature Publishing Group
Leukemia, 32, 383-390
Leukemia, 32, 2, pp. 383-390
Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, L, Salwender, H J & Sonneveld, P 2018, ' Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial ', Leukemia, vol. 32, no. 2, pp. 383-390 . https://doi.org/10.1038/leu.2017.211
Leukemia, 32(2), 383. Nature Publishing Group
Leukemia, 32, 383-390
The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell trans
Autor:
Pierre Zachee, Elliott F. Winton, Alessandro M. Vannucchi, Sonja Zweegman, Ruben A. Mesa, Joanne Lager, Harry C. Schouten, Claire N. Harrison, Jean-Jacques Kiladjian, Ramon V. Tiu, Moshe Talpaz, Francesco Passamonti, Richard T. Silver, Nicolaas Schaap, Eric Jourdan, Zhenming Shun
Publikováno v:
Harrison, C N, Schaap, N, Vannucchi, A M, Kiladjian, J J, Tiu, R V, Zachee, P, Jourdan, E, Winton, E, Silver, R T, Schouten, H C, Passamonti, F, Zweegman, S, Talpaz, M, Lager, J, Shun, Z & Mesa, R A 2017, ' Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2) : a single-arm, open-label, non-randomised, phase 2, multicentre study ', The Lancet Haematology, vol. 4, no. 7, pp. e317-e324 . https://doi.org/10.1016/S2352-3026(17)30088-1
Lancet Haematology, 4, 7, pp. e317-e324
Lancet Haematology, 4, e317-e324
The Lancet Haematology, 4(7), E317-E324. ELSEVIER SCI LTD
The Lancet Haematology, 4(7), e317-e324. Lancet Publishing Group
Lancet Haematology, 4, 7, pp. e317-e324
Lancet Haematology, 4, e317-e324
The Lancet Haematology, 4(7), E317-E324. ELSEVIER SCI LTD
The Lancet Haematology, 4(7), e317-e324. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: Myelofibrosis is a chronic myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including fatigue, weight loss, and bone pain. Mutations in J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e26ba428c1b4f6196757a066ed54349
https://research.vumc.nl/en/publications/6d8e1497-f30c-4de7-81c0-86b1cbbdc6f1
https://research.vumc.nl/en/publications/6d8e1497-f30c-4de7-81c0-86b1cbbdc6f1
Autor:
Robyn M. Scherber, Claire N. Harrison, Ruben A. Mesa, Stefanie Slot, Junqing Xu, Jean-Jacques Kiladjian, Zefeng Xu, Pablo J. Muxi, Chiara Paoli, Harry C. Schouten, Lydia Roy, Peter A. W. te Boekhorst, Robert Peter Gale, Norman Maldonado, Thomas Lehmann, Karin Bonatz, Maria Luisa Ferrari, Federico Sackmann, Jean Christophe Ianotto, Peihong Zhang, Giovanni Barosi, Alessandro Rambaldi, Bjorn Andreasson, Peter L. Johansson, Xiujuan Sun, Allison H. Scotch, Ana Kerguelen Fuentes, Jean-Yves Cahn, Deepti Radia, Suzan Commandeur, Zhijian Xiao, Jan Samuelsson, Heidi E. Kosiorek, Francisco Cervantes, Yue Zhang, Gabriel Etienne, Heike L. Pahl, Françoise Boyer, Martin Griesshammer, Francesco Passamonti, Konstanze Döhner, Gunnar Birgegård, Sonja Zweegman, Carlos Besses, Alessandro M. Vannucchi, Dana Ranta, Frank Stegelmann, Dolores Hernández-Maraver, Amylou C. Dueck, Holly L. Geyer, Tiziano Barbui, Andreas Reiter
Publikováno v:
Leukemia Research, 63, 34-40. Elsevier Ltd.
Scotch, A H, Kosiorek, H, Scherber, R, Dueck, A C, Slot, S, Zweegman, S, Boekhorst, P A W T, Commandeur, S, Schouten, H, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J C, Ranta, D, Roy, L, Cahn, J Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J J, Zhang, P, Gale, R P, Mesa, R A & Geyer, H L 2017, ' Symptom burden profile in myelofibrosis patients with thrombocytopenia : Lessons and unmet needs ', Leukemia Research, vol. 63, pp. 34-40 . https://doi.org/10.1016/j.leukres.2017.10.002
Leukemia Research, 63, 34-40. Elsevier Limited
Leuk Res
Scotch, A H, Kosiorek, H, Scherber, R, Dueck, A C, Slot, S, Zweegman, S, Boekhorst, P A W T, Commandeur, S, Schouten, H, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J C, Ranta, D, Roy, L, Cahn, J Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J J, Zhang, P, Gale, R P, Mesa, R A & Geyer, H L 2017, ' Symptom burden profile in myelofibrosis patients with thrombocytopenia : Lessons and unmet needs ', Leukemia Research, vol. 63, pp. 34-40 . https://doi.org/10.1016/j.leukres.2017.10.002
Leukemia Research, 63, 34-40. Elsevier Limited
Leuk Res
Myelofibrosis is a myeloproliferative neoplasm associated with progressive cytopenias and high symptom burden. MF patients with thrombocytopenia have poor prognosis but the presence of thrombocytopenia frequently precludes the use of JAK2 inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022b1a49d48b9e484baa96dcb56756c9
http://hdl.handle.net/11383/2066806
http://hdl.handle.net/11383/2066806
Autor:
Pierre W. Wijermans, Pieter Sonneveld, Mario Boccadoro, Massimo Offidani, Alessandra Larocca, Jesús F. San Miguel, Valeria Magarotto, Meral Beksac, Gunnar Juliusson, Chiara Cerrato, Paola Omedè, Maria-Victoria Mateos, Pellegrino Musto, Antonio Palumbo, Anna Marina Liberati, Albert Oriol, Michele Cavo, Daniela Gottardi, Massimo Gentile, Sara Bringhen, Carla Mazzone, Fortunato Morabito, Davide Rossi, Ana Isabel Turel, Maide Cavalli, Peter Gimsing, Martijn R. Schaafsma, Roberto Passera, Sonja Zweegman, Anders Waage, Lucio Catalano, Juan José Lahuerta, Stefano Rosso, Renato Zambello
Publikováno v:
American Journal of Hematology. 89:355-362
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide
Autor:
F.S. Dijkstra, Sonja Zweegman, Gert J. Ossenkoppele, Otto Visser, Birgit I. Witte, Marielle J. Wondergem, Jeroen Janssen
Publikováno v:
Wondergem, M J, Dijkstra, F S, Visser, O J, Zweegman, S, Ossenkoppele, G J, Witte, B I & Janssen, J J W M 2014, ' Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies ', Bone Marrow Transplantation, vol. 49, no. 4, pp. 513-518 . https://doi.org/10.1038/bmt.2013.221
Bone Marrow Transplantation, 49(4), 513-518. Nature Publishing Group
Bone Marrow Transplantation, 49(4), 513-518. Nature Publishing Group
We studied the outcome of allo-SCT after reduced-intensity conditioning in relapsed or refractory indolent and aggressive lymphoid malignancies. All 54 patients (diagnosis: B-CLL n=13, indolent lymphoma n=12, aggressive lymphoma n=13, transformed lym
Autor:
Peihong Zhang, Giovanni Barosi, Zefeng Xu, Alessandro M. Vannucchi, Chiara Paoli, Carlos Besses, Bjorn Andreasson, Peter L. Johansson, Peter A. W. te Boekhorst, Xiujuan Sun, Jan Samuelsson, Gunnar Birgegård, Yue Zhang, Ana Kerguelen Fuentes, Dana Ranta, Ruben A. Mesa, Keith Cannon, Dolores Hernández-Maraver, Andreas Reiter, Robyn M. Scherber, Jean-Yves Cahn, Amylou C. Dueck, Heike L. Pahl, Lydia Roy, Karin Bonatz, Pablo J. Muxi, Zhenya Senyak, Jean-Jacques Kiladjian, Gabriel Etienne, Holly L. Geyer, Stefanie Slot, Robert Peter Gale, Claire N. Harrison, Frank Stegelmann, Federico Sackmann, Francesco Passamonti, Jean Christophe Ianotto, Heidi E. Kosiorek, Martin Griesshammer, Harry C. Schouten, Sonja Zweegman, Norman Maldonado, Maria Luisa Ferrari, Alessandro Rambaldi, Francisco Cervantes, Deepti Radia, Konstanze Döhner, Zhijian Xiao, Tiziano Barbui, Thomas Lehmann, Françoise Boyer, Junqing Xu
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Haematologica, 102(1), 85-93. Ferrata Storti Foundation
Haematologica-the Hematology Journal, 102(1), 85-93. Ferrata Storti Foundation
Geyer, H L, Kosiorek, H, Dueck, A C, Scherber, R, Slot, S, Zweegman, S, Te Boekhorst, P A, Senyak, Z, Schouten, H C, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J-C, Ranta, D, Roy, L, Cahn, J-Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Cannon, K, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J-J, Zhang, P, Gale, R P & Mesa, R A 2017, ' Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms : an analysis by the MPN QOL International Working Group ', Haematologica, vol. 102, no. 1, pp. 85-93 . https://doi.org/10.3324/haematol.2016.149559
Consejería de Sanidad de la Comunidad de Madrid
Haematologica, 102(1), 85-93. Ferrata Storti Foundation
Haematologica-the Hematology Journal, 102(1), 85-93. Ferrata Storti Foundation
Geyer, H L, Kosiorek, H, Dueck, A C, Scherber, R, Slot, S, Zweegman, S, Te Boekhorst, P A, Senyak, Z, Schouten, H C, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J-C, Ranta, D, Roy, L, Cahn, J-Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Cannon, K, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J-J, Zhang, P, Gale, R P & Mesa, R A 2017, ' Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms : an analysis by the MPN QOL International Working Group ', Haematologica, vol. 102, no. 1, pp. 85-93 . https://doi.org/10.3324/haematol.2016.149559
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gend
Autor:
Bronno van der Holt, Anders Waage, Niels W.C.J. van de Donk, E. (Vera) J. M. Mattijssen, M. (Rineke) B. L. Leys, Annette W. G. van der Velden, Mark-David Levin, Harm Sinnige, Klaas G. van der Hem, Morten Salomo, Bea Tanis, Einar Haukås, Ulf-Henrik Mellqvist, Matthijs Westerman, Rolf Brouwer, Pieter Sonneveld, Saskia K. Klein, Astrid Gruber, Gerard M. J. Bos, Marian Stevens-Kroef, Markus Hansson, Damian L. Szatkowski, Wendy Deenik, Torben Plesner, Sonja Zweegman, Marc Durian, Heleen Visser-Wisselaar, Juleon Coenen
Publikováno v:
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M R B L, Sinnige, H A M, Haukås, E, van der Hem, K G, Durian, M F, Mattijssen, E V J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127(9), 1109-1116. American Society of Hematology
Blood, 127(9), 1109-1116. The American Society of Hematology
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M B L, Sinnige, H A M, Haukas, E, van der Hem, K G, Durian, M F, Mattijssen, E J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127, 1109-16
Blood, 127, 9, pp. 1109-16
Blood, 127(9), 1109-1116. American Society of Hematology
Blood, 127(9), 1109-1116. The American Society of Hematology
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M B L, Sinnige, H A M, Haukas, E, van der Hem, K G, Durian, M F, Mattijssen, E J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127, 1109-16
Blood, 127, 9, pp. 1109-16
The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation. Long-term treatment with thalidomide is hampered by ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27be0ae01cb43dea87bdd45a3473c8b5
https://portal.findresearcher.sdu.dk/da/publications/767d554b-0302-426c-b3cf-03650e95cbc9
https://portal.findresearcher.sdu.dk/da/publications/767d554b-0302-426c-b3cf-03650e95cbc9
Autor:
Bjorn Andreasson, Peter L. Johansson, Federico Sackmann, Giovanni Barosi, Zhijian Xiao, Françoise Boyer, Ruben A. Mesa, Suzan Commandeur, Carlos Besses, Tiziano Barbui, Norman Maldonado, Maria Luisa Ferrari, Peter A. W. te Boekhorst, Francisco Cervantes, Jean-Jacques Kiladjian, Yue Zhang, Zhenya Senyak, Harry C. Schouten, Karin Bonatz, Konstanze Döhner, Dana Ranta, Zefeng Xu, Jan Samuelsson, Jean-Yves Cahn, Francesco Passamonti, Deepti Radia, Andreas Reiter, Sonja Zweegman, Xiujuan Sun, Alessandro Rambaldi, Ana Kerguelen Fuentes, Junqing Xu, Thomas Lehmann, Lydia Roy, Gabriel Etienne, Alessandro M. Vannucchi, Heidi E. Kosiorek, Jean Christophe Ianotto, Martin Griesshammer, Peihong Zhang, Robert Peter Gale, Heike L. Pahl, Gunnar Birgegård, Claire N. Harrison, Frank Stegelmann, Robyn M. Scherber, Pablo J. Muxi, Stefanie Slot, Dolores Hernández-Maraver, Amylou C. Dueck, Holly L. Geyer
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩
Geyer, H, Scherber, R, Kosiorek, H, Dueck, A C, Kiladjian, J-J, Xiao, Z, Slot, S, Zweegman, S, Sackmann, F, Kerguelen Fuentes, A, Hernandez-Maraver, D, Doehner, K, Harrison, C N, Radia, D, Muxi, P, Besses, C, Cervantes, F, Johansson, P L, Andreasson, B, Rambaldi, A, Barbui, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J-C, Ranta, D, Roy, L, Cahn, J-Y, Maldonado, N, Barosi, G, Ferrari, M L, Gale, R P, Birgegard, G, Xu, Z, Zhang, Y, Sun, X, Xu, J, Zhang, P, te Boekhorst, P A W, Commandeur, S, Schouten, H, Pahl, H L, Griesshammer, M, Stegelmann, F, Lehmann, T, Senyak, Z, Vannucchi, A M, Passamonti, F, Samuelsson, J & Mesa, R A 2016, ' Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease ', Journal of Clinical Oncology, vol. 34, no. 2, pp. 151-+ . https://doi.org/10.1200/JCO.2015.62.9337
Journal of Clinical Oncology, 34(2), 151-+. American Society of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩
Journal of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩
Geyer, H, Scherber, R, Kosiorek, H, Dueck, A C, Kiladjian, J-J, Xiao, Z, Slot, S, Zweegman, S, Sackmann, F, Kerguelen Fuentes, A, Hernandez-Maraver, D, Doehner, K, Harrison, C N, Radia, D, Muxi, P, Besses, C, Cervantes, F, Johansson, P L, Andreasson, B, Rambaldi, A, Barbui, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J-C, Ranta, D, Roy, L, Cahn, J-Y, Maldonado, N, Barosi, G, Ferrari, M L, Gale, R P, Birgegard, G, Xu, Z, Zhang, Y, Sun, X, Xu, J, Zhang, P, te Boekhorst, P A W, Commandeur, S, Schouten, H, Pahl, H L, Griesshammer, M, Stegelmann, F, Lehmann, T, Senyak, Z, Vannucchi, A M, Passamonti, F, Samuelsson, J & Mesa, R A 2016, ' Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease ', Journal of Clinical Oncology, vol. 34, no. 2, pp. 151-+ . https://doi.org/10.1200/JCO.2015.62.9337
Journal of Clinical Oncology, 34(2), 151-+. American Society of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩
Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients
Autor:
Michele Cavo, Andrew Spencer, Meletios A. Dimopoulos, Roman Hájek, Martin Gramatzki, Orhan Sezer, Pieter Sonneveld, Antonio Palumbo, Sonja Zweegman, Sara Bringhen, Henk M. Lokhorst, Faith E. Davies, Heinz Ludwig, Joan Bladé, Maria V. Mateos, Gareth J. Morgan, Hans Erik Johnsen, Peter Gimsing, Jesús F. San Miguel, Laura Rosiñol, Meral Beksac, Evangelos Terpos, Christoph Driessen, Hermann Einsele, Fernando Leal da Costa, Mario Boccadoro
Publikováno v:
Blood, 118(17), 4519-4529. American Society of Hematology
Palumbo, A, Bringhen, S, Ludwig, H, Dimopoulos, M A, Bladé, J, Mateos, M V, Rosiñol, L, Boccadoro, M, Cavo, M, Lokhorst, H, Zweegman, S, Terpos, E, Davies, F, Driessen, C, Gimsing, P, Gramatzki, M, Hàjek, R, Johnsen, H E, Leal Da Costa, F, Sezer, O, Spencer, A, Beksac, M, Morgan, G, Einsele, H, San Miguel, J F & Sonneveld, P 2011, ' Personalized therapy in multiple myeloma according to patient age and vulnerability : a report of the European Myeloma Network (EMN) ', Blood, vol. 118, no. 17, pp. 4519-29 . https://doi.org/10.1182/blood-2011-06-358812
Digital.CSIC. Repositorio Institucional del CSIC
instname
Palumbo, A, Bringhen, S, Ludwig, H, Dimopoulos, M A, Blade, J, Mateos, M V, Rosinol, L, Boccadoro, M, Cavo, M, Lokhorst, H, Zweegman, S, Terpos, E, Davies, F, Driessen, C, Gimsing, P, Gramatzki, M, Hajek, R, Johnsen, H E, Da Costa, F L, Sezer, O, Spencer, A, Beksac, M, Morgan, G, Einsele, H, Miguel, J F S & Sonneveld, P 2011, ' Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) ', Blood, vol. 118, no. 17, pp. 4519-4529 . https://doi.org/10.1182/blood-2011-06-358812
Palumbo, A, Bringhen, S, Ludwig, H, Dimopoulos, M A, Bladé, J, Mateos, M V, Rosiñol, L, Boccadoro, M, Cavo, M, Lokhorst, H, Zweegman, S, Terpos, E, Davies, F, Driessen, C, Gimsing, P, Gramatzki, M, Hàjek, R, Johnsen, H E, Leal Da Costa, F, Sezer, O, Spencer, A, Beksac, M, Morgan, G, Einsele, H, San Miguel, J F & Sonneveld, P 2011, ' Personalized therapy in multiple myeloma according to patient age and vulnerability : a report of the European Myeloma Network (EMN) ', Blood, vol. 118, no. 17, pp. 4519-29 . https://doi.org/10.1182/blood-2011-06-358812
Digital.CSIC. Repositorio Institucional del CSIC
instname
Palumbo, A, Bringhen, S, Ludwig, H, Dimopoulos, M A, Blade, J, Mateos, M V, Rosinol, L, Boccadoro, M, Cavo, M, Lokhorst, H, Zweegman, S, Terpos, E, Davies, F, Driessen, C, Gimsing, P, Gramatzki, M, Hajek, R, Johnsen, H E, Da Costa, F L, Sezer, O, Spencer, A, Beksac, M, Morgan, G, Einsele, H, Miguel, J F S & Sonneveld, P 2011, ' Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) ', Blood, vol. 118, no. 17, pp. 4519-4529 . https://doi.org/10.1182/blood-2011-06-358812
Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise o